Riccaboni

Slide1: 

University-Industry linkages: Local institutional embeddedness Fabio Pammolli, Massimo Riccaboni University of Florence & CERM, Rome Menaggio, 9-10 May 2005

EU Competitiveness Reports: 

EU Competitiveness Reports Global Competitiveness in Pharmaceuticals. A European Perspective, 2001, EC, DG Enterprise Innovation and Competitiveness in European Biotechnology, 2002, EC, DG Enterprise. Medical Devices Competitiveness and Impact on Public Health Expenditure, EC, DG Enterprise forthcoming.

University-industry linkages: 

University-industry linkages the movement of university graduates into commercial firms; consulting relations between faculty and companies; licensing of university technologies; industry gifts supporting university research and student training; faculty entrepreneurship leading to the founding of new companies; faculty involvement on scientific advisory boards; co-patenting between university and industry scientists; formal contractual partnerships to pursue joint R&D, product or prototype co-development.

Knowledge spillovers: 

Knowledge spillovers Knowledge spillovers are geographically localized (Audresch and Feldman, 1996; Feldman, 1994; Jaffe 1989; Jaffe et al, 1993) University research as a positive effect on the productivity of local firms (Jaffe, 1989; Zucker and Darby, 1997) The assumption that publicly funded knowledge “spills over” from publicly funded institutions universities and laboratories is an integral part of the economic justification for their existence; The existence of knowledge spillovers is fundamental to the theory of endogenous growth: the engines of national economic performances are subnational innovation districts. Knowledge spillovers decline with market, technological and geographical distance.

Knowledge spillovers: 

Knowledge spillovers Furman et al. (2004) Knowledge spillovers exist and are significant; Patent output is positively correlated with a firm’s “exposure” to papers in the same technological field authored by scientists within thirty-five miles of where the firm conducts research; Patent output is positively and significantly correlated with publicly authored work, but negatively and significantly correlated with private sector work; Results hold for both locally and globally generated work, with the effects being strongest for locally authored work but significant at both levels.

Slide6: 

Citations to UC Berkeley Papers Source: Branstetter (2003) CLUSTERS

Slide7: 

CLUSTERING (1) Lieden, (2) Amsterdam, (3) Groningen, (4) Wageningen, (5) Utrecht, (6) Lelystad, (7) Nijmegen, (8) Delft, and (9) Maastricht.

Networks: 

Networks Collaborations in Genomic R&D

Slide10: 

EU-US COLLABORATIONS

Slide11: 

Collaborative R&D Projects originated and developed by country and partners' location

Slide12: 

Patent Co-Assignment Network: PROs

Slide13: 

Patent Co-Assignment Network: PROs and private companies

Slide14: 

Collaborative R&D projects: PROs and private companies

Slide16: 

Patent Co-Assignment Network: Leading PROs

Slide17: 

Founder affiliation network – Boston, 1978-2003 NODE LEGEND Circle: DBF Triangle: PRO Square: VC, pharmaceutical, or other business Porter et al., 2005

Boston Patent Co-Inventor Network, 1976-1998 : 

Boston Patent Co-Inventor Network, 1976-1998 NODE LEGEND White Circle = University Inventor (66%, N = 599) Gray Circle = DBF Inventor (28%, N = 257) Square = University and DBF (2.5%, N = 23) ---------------------------- Triangle = Founder (1.7%, N=15) Diamond = SAB Member (1.4%, N = 13) Porter et al., 2005

Slide19: 

Universities and SMEs: the Swedish Biotech R&D Network University/local MNC/global

Main european clusters: 

Main european clusters

Agglomeration economies: 

Agglomeration economies

Slide22: 

REACHING-OUT

Mission Bay & QB3: 

Mission Bay & QB3 Mission Bay, UCSF, San Francisco

Slide24: 

PharmaSTART™ PharmaSTART™ is a consortium of research organizations led by SRI International that offers translational drug development services to help California-based universities, research institutes, and small biotech companies bridge the gap between identifying exciting new drug discoveries and bringing them successfully through clinical development. The goal of PharmaSTART is to facilitate the translation and funding of discovery research from California based Universities and their small cap companies, by offering drug development consulting, networking, and drug development services including lead development, GLP toxicology, analytical and regulatory services and cGMP manufacturing. Center for BioEntrepreneurship The UC San Francisco Center for BioEntrepreneurship (CBE) hosts a series of lectures, symposia and courses to educate the UC San Francisco community on entrepreneurship and business in life sciences. Entrepreneurship Bridging the gap

Industry and Venture Capital Partnerships: 

The recently launched Synthetic Biology Corporate Consortium invites industry and venture capital firms to participate in the newly formed Synthetic Biology Center. The consortium will ensure that research focuses on questions of science and technology critical to industry; speed the transfer of technologies and innovation to industry; and increase industry access to research results, publications, tools, graduate students, faculty, and facilities. Member benefits will include research symposia, a quarterly research newsletter, access to graduate and undergraduate students, representation on the Center's advisory committee and intellectual property access. Industry and Venture Capital Partnerships Venture capital

Interdisciplinary research: Computational Biology: 

Interdisciplinary research: Computational Biology At UC Berkeley, QB3 has facilitated the development of the Computational Biology Initiative (CBI), which features undergraduate and graduate education components, including the newly created Graduate Group in Computational and Genomic Biology. At UC San Francisco, master's and doctoral students may complete a School of Pharmacy graduate program specifically designed to train biomedical informatics researchers for academic and industry. At UC Santa Cruz, the School of Engineering now offers bachelor’s, master’s, and doctoral degrees in bioinformatics. Interdisciplinary research

Stockholm Bioscience: 

Stockholm Bioscience Political awareness of the opportunities = zero Land owners = multiple, no cooperation Collaboration across Stockholm and Solna city boundaries = zero 1999 City of Solna City of Stockholm Regional collaboration = zero Collaboration between universities = potential for more

Stockholm BioScience 4-5 years later: 

City of Solna City of Stockholm KI Karolinska University Hospital Stockholm BioScience 4-5 years later KTH SU A new city section under way… Strong political support Public sector owns the land Planning of a new university hospital Planning of public transportation (subway and commuter train) Inter-city collaboration 2004 SSE “Stockholm – a city of science” established Increased multi-disciplinary collaboration Stockholm BioRegion established

Stockholm BioScience in 8-10 years: 

City of Stockholm KI Karolinska University Hospital Stockholm BioScience in 8-10 years SU KTH 2012 A new city section of Stockholm World-class science in new research facilities A cluster of life-science companies The new university hospital inaugurated A global address in bioscience “Stockholm – a city of science” City of Solna SSE